- Clinical Trials
- April 2024
- 50 Pages
Global
From €1441EUR$1,500USD£1,232GBP
- Report
- March 2024
- 187 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- March 2024
- 147 Pages
Global
From €3746EUR$3,899USD£3,203GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4756EUR$4,950USD£4,066GBP
- Report
- February 2022
- 113 Pages
Global
From €7206EUR$7,500USD£6,161GBP
Vascular Dementia Drug is a type of drug used to treat vascular dementia, a form of dementia caused by reduced blood flow to the brain. These drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. Vascular dementia drugs are typically used to improve cognitive function, reduce symptoms, and slow the progression of the disease. Commonly used drugs include cholinesterase inhibitors, memantine, and other drugs that target specific neurotransmitters.
The CNS drug market is highly competitive, with many large pharmaceutical companies competing for market share. Companies in the Vascular Dementia Drug market include Pfizer, Novartis, Merck, and Johnson & Johnson. Other companies, such as Allergan, AstraZeneca, and Eli Lilly, also have products in the CNS drug market. Show Less Read more